Form 4: Abbott Laboratories Director Michael F. Roman Reports Stock Equivalent Unit Acquisition

Director Michael F. Roman reported the acquisition of 311 stock equivalent units in Abbott Laboratories on December 31, 2024, according to a Form 4 filing.

Summary

• On December 31, 2024, Michael F. Roman, a director of Abbott Laboratories, acquired 311 stock equivalent units.
• These units were acquired as director fees and are credited to a stock equivalent unit account.
• The fees are generally paid in cash at age 65 or upon retirement from the board.
• The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
• The price of the stock equivalent units was $113.11.
• Following the transaction, Roman directly owns 4,670 derivative securities.
• The balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard director compensation practices and alignment of interests.

Positives

• The acquisition of stock equivalent units reflects continued alignment of the director's interests with those of the shareholders.

Future Outlook

The stock equivalent units will be paid out in cash generally at age 65 or upon retirement from the board.

Industry Context

Directors commonly receive stock options or equivalent units as part of their compensation, aligning their interests with the long-term performance of the company.

Stakeholder Impact

• The acquisition of stock equivalent units aligns the director's interests with those of the shareholders.

Key Dates